Oxford Biomedica (France) S.A.S
Oxford Biomedica (France) S.A.S is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.
Sponsor MaaT PHARMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The study enrolled 67 subjects versus 75 planned, with 66 subjects treated and included in the efficacy and safety analysis sets.
- Subjects were enrolled in France, Spain, Belgium, Italy, Germany, and Austria.
- The exclusion criterion for liver Stage 4 and/or skin Stage 4 acute graft-versus-host disease was removed in protocol Version 5.0 dated 10 August 2022.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Oxford Biomedica (France) S.A.S?
The 2026-10-09 snapshot links Oxford Biomedica (France) S.A.S to 1 distinct CTIS trials. Recorded services include Medicical product manufacturer. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Oxford Biomedica (France) S.A.S?
The most frequently recorded therapeutic areas are Gastroenterology, Immunology, Transplantation. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Oxford Biomedica (France) S.A.S conducted?
The linked trials record locations in 6 countries, including Austria, Belgium, Germany, Spain, France. These are trial locations, not confirmed office locations or countries where Oxford Biomedica (France) S.A.S delivered services.
What can this page tell me about Oxford Biomedica (France) S.A.S's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Oxford Biomedica (France) S.A.S. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Oxford Biomedica (France) S.A.S.